Amicus Therapeutics Inc (FOLD) concluded trading on Thursday at a closing price of $5.95, with 4.21 million shares of worth about $25.07 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -44.34% during that period and on May 15, 2025 the price saw a gain of about 1.19%. Currently the company’s common shares owned by public are about 307.92M shares, out of which, 297.53M shares are available for trading.
Stock saw a price change of -2.14% in past 5 days and over the past one month there was a price change of -13.77%. Year-to-date (YTD), FOLD shares are showing a performance of -36.84% which decreased to -34.18% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.82 but also hit the highest price of $12.65 during that period. The average intraday trading volume for Amicus Therapeutics Inc shares is 3.82 million. The stock is currently trading -10.51% below its 20-day simple moving average (SMA20), while that difference is down -21.06% for SMA50 and it goes to -38.35% lower than SMA200.
Amicus Therapeutics Inc (NASDAQ: FOLD) currently have 307.92M outstanding shares and institutions hold larger chunk of about 96.20% of that.
The stock has a current market capitalization of $1.83B and its 3Y-monthly beta is at 0.53. It has posted earnings per share of -$0.09 in the same period. It has Quick Ratio of 2.47 while making debt-to-equity ratio of 2.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FOLD, volatility over the week remained 3.86% while standing at 4.35% over the month.
Stock’s fiscal year EPS is expected to rise by 51.94% while it is estimated to increase by 398.57% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on December 13, 2024 offering an Equal-weight rating for the stock and assigned a target price range of between $17 and $12 to it. Coverage by Jefferies stated Amicus Therapeutics Inc (FOLD) stock as a Buy in their note to investors on September 06, 2024, suggesting a price target of $18 for the stock. On May 30, 2024, Wells Fargo Initiated their recommendations, while on May 14, 2024, Guggenheim Upgrade their ratings for the stock with a price target of $13. Stock get an Overweight rating from Morgan Stanley on December 19, 2023.
